Isocitrate dehydrogenase [NADP] cytoplasmic


  • Accession: O75874
  • Swissprot: IDHC_HUMAN
  • Organism: Homo sapiens
  • Gene: IDH1
  • Target classes: Enzyme, Unclassified

Drug Relations:

Ivosidenib is a small molecule inhibitor that targets the mutant isocitrate dehydrogenase 1 (IDH1) enzyme. Susceptible IDH1 mutations are defined as those leading to increased levels of 2-hydroxyglutarate(2-HG) in the leukemia cells and where efficacy is predicted by 1) clinically meaningful remissions with the recommended dose of ivosidenib and/or 2) inhibition of mutant IDH1 enzymatic activity at concentrations of ivosidenib sustainable at the recommended dosage according to validated methods. The most common of such mutations are R132H and R132C substitutions. Bioactivity details MOA